← Back to Screener
Korro Bio, Inc. Common Stock (KRRO)
Price$14.28
Favorite Metrics
Price vs S&P 500 (26W)-75.26%
Price vs S&P 500 (4W)24.37%
Market Capitalization$207.54M
All Metrics
Book Value / Share (Quarterly)$5.46
P/TBV (Annual)4.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-23.12%
Cash Flow / Share (Quarterly)$-8.40
Price vs S&P 500 (YTD)75.51%
Net Profit Margin (TTM)-1834.48%
EPS (TTM)$-12.47
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-12.47
Revenue Growth (5Y)-26.07%
EPS (Annual)$-12.48
ROI (Annual)-227.96%
Gross Margin (Annual)44.73%
Net Profit Margin (5Y Avg)-1161.48%
Cash / Share (Quarterly)$7.98
Revenue Growth QoQ (YoY)-43.11%
ROA (Last FY)-103.31%
EBITD / Share (TTM)$-11.96
ROE (5Y Avg)-87.08%
Operating Margin (TTM)-1906.37%
Cash Flow / Share (Annual)$-8.40
P/B Ratio4.03x
P/B Ratio (Quarterly)1.47x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)29.05x
Net Interest Coverage (TTM)-57.71x
ROA (TTM)-71.32%
EPS Incl Extra (Annual)$-12.48
Current Ratio (Annual)6.90x
Quick Ratio (Quarterly)6.38x
3-Month Avg Trading Volume0.23M
52-Week Price Return6.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$49.74
P/S Ratio (Annual)32.47x
Asset Turnover (Annual)0.06x
52-Week High$55.89
Operating Margin (5Y Avg)-1270.34%
EPS Excl Extra (Annual)$-12.48
CapEx CAGR (5Y)-40.02%
Tangible BV CAGR (5Y)32.33%
26-Week Price Return-66.51%
Quick Ratio (Annual)6.38x
13-Week Price Return59.89%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.90x
Enterprise Value$185.717
Revenue / Share Growth (5Y)-6.05%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)29.09%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1824.52%
Cash / Share (Annual)$7.98
3-Month Return Std Dev84.53%
Net Income / Employee (TTM)$-2
ROE (Last FY)-227.96%
Net Interest Coverage (Annual)-36.96x
EPS Basic Excl Extra (Annual)$-12.48
Receivables Turnover (TTM)4.80x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-12.47
Receivables Turnover (Annual)4.80x
ROI (TTM)-115.95%
P/S Ratio (TTM)32.47x
Pretax Margin (5Y Avg)-1158.23%
Revenue / Share (Annual)$0.68
Tangible BV / Share (Annual)$98.12
Price vs S&P 500 (52W)-28.19%
Year-to-Date Return79.65%
5-Day Price Return5.11%
EPS Normalized (Annual)$-12.48
ROA (5Y Avg)-54.56%
Net Profit Margin (Annual)-1834.48%
Month-to-Date Return27.12%
Cash Flow / Share (TTM)$-79.22
EBITD / Share (Annual)$-11.96
Operating Margin (Annual)-1906.37%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-87.08%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-12.47
P/TBV (Quarterly)8.34x
P/B Ratio (Annual)1.47x
Pretax Margin (TTM)-1824.52%
Book Value / Share (Annual)$5.46
Price vs S&P 500 (13W)57.02%
Beta3.15x
P/FCF (Annual)6.26x
Revenue / Share (TTM)$0.68
ROE (TTM)-115.95%
52-Week Low$5.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.56
3.75
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KRROKorro Bio, Inc. Common Stock | 32.47x | — | — | — | $14.28 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Korro Bio is a biopharmaceutical company developing RNA-editing genetic medicines to treat rare and prevalent diseases. The company's proprietary platform leverages the body's natural RNA editing process to create precise, transient single-base edits with greater reversibility than traditional DNA-editing approaches. This differentiated technology positions Korro Bio to address significant unmet medical needs in genetic medicine with enhanced precision and tunability.